PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Visiongain

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Neuroprotection Market to Reach $2.6 Billion in 2014 Says Visiongain Report - A new report by visiongain predicts that the overall world market for neuroprotective products will reach $2.6 billion for 2014 - Visiongain.com
Neuroprotection Market to Reach $2.6 Billion in 2014 Says Visiongain Report

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/05/15 - A new report by visiongain predicts that the overall world market for neuroprotective products will reach $2.6 billion for 2014 - Visiongain.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

That revenue forecast appears in Neuroprotective Products: World Market Prospects 2012-2022, published in May 2012. Visiongain is a business information provider based in London, UK.

Visiongain forecasts that the neuroprotection products market will achieve strong revenue growth to 2022, especially from 2017. By then, many clinical trials will have finished and drugs will gain regulatory approval. The scope of the field is widening, with many organisations entering and collaborating.

The pharmaceutical industry will develop more treatments for neuronal protection, with high revenues possible this decade and beyond. The R&D pipeline is strong and promising, the study reports. The main aim of drug developers is to prevent neuronal death and revive damaged neurons (neuroregeneration). Not all neuroprotective agents will be neuroregenerative, however.

Kritika Chaudhari, a pharmaceutical industry analyst in visiongain, explains: “The emerging neuroprotection market in 2012 depends on the success of its R&D pipeline. The medical community regards neuroprotection as an important need in treating acute and chronic neurological conditions. Regulatory agencies also recognise the therapeutic potential of neuroprotective agents and have granted fast track designation and orphan drug status to product candidates. The strong R&D pipeline of neuroprotective agents offers marked sales potential after drug approvals.”

Rising incidence and prevalence of neurodegenerative diseases in ageing populations will stimulate that treatment market. Another force driving the industry and market will be the treatment of brain injuries, especially those from traffic accidents.

Visiongain’s report provides revenue forecasts to 2022 at overall world market, therapeutic submarket and product level. It forecasts world sales for the following submarkets:

• Ion channel modulators;
• Mitochondrial dysfunction regulators;
• Anti-inflammatory and anti-apoptotic agents;
• Neurotrophic factors;
• Other neuroprotective treatments.

That investigation forecasts sales of leading agents, including Rasagiline, Minocycline, Memantine and NeuroSTAT. Research, data and analyses cover activities of Ceregene, Genervon Biopharmaceuticals, Neuren Pharmaceuticals and other pharmaceutical companies.

The analysis also contains research interviews with authorities in the industry. Neuroprotective Products: World Market Prospects 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report Neuroprotective Products: World Market Prospects 2012-2022, please visit the website.

About visiongain
Visiongain (visiongain.com) is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Visiongain

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Neuroprotection Market to Reach $2.6 Billion in 2014 Says Visiongain Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongainglobal.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Visiongain / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)